CDK4 and breast carcinoma: Based on the insights into B7-H4 degradation via lysosomes, we find that abemaciclib, an FDA-approved CDK4/6 inhibitor for breast cancer, reduces B7-H4 protein levels by enhancing lysosome biogenesis and abundance.